-+ 0.00%
-+ 0.00%
-+ 0.00%

Keybanc Maintains Overweight on ResMed, Raises Price Target to $267

Benzinga·08/31/2026 12:24:34
Listen to the news
Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and raises the price target from $255 to $267.